A carregar...

BRAF-directed Therapy in Metastatic Colorectal Cancer

Activating BRAF mutations occur in approximately 5–10% of metastatic colorectal cancer (mCRC) patients, mostly V600E mutation, and it is associated with distinct clinical and pathological features. To date, there are no approved treatments to target this mutation. BRAF inhibitor monotherapy has limi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer J
Main Authors: Korphaisarn, Krittiya, Kopetz, Scott
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4922502/
https://ncbi.nlm.nih.gov/pubmed/27341594
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0000000000000189
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!